$DERM

Journey Medical Corp

Journey Medical is a commercial-stage pharmaceutical company that sells and markets FDA-approved prescription products for dermatological conditions, primarily in the United States. Its portfolio includes eight FDA-approved drugs, marketed through its field sales organization. Major products include Emrosi for rosacea, Qbrexza for excessive underarm sweating, Accutane and Amzeeq for acne, and Zilxi for rosacea. The company also sells legacy products including Exelderm, Targadox and Luxamend. Journey Medical acquires or licenses product rights and may fund development before commercializing products. Journey Medical sells mainly to specialty pharmacies, independent wholesalers and distributors, which supply pharmacies and other customers. It also earns royalties on sales of Amzeeq by Cutia in China. The company is headquartered in Scottsdale, Arizona, and has 58 full-time employees as of March 18, 2026.

1
2
1

No SEC Form 4 filings for $DERM in the last 30 days.

See all $DERM insider activity →

Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate

Journey Medical Corp (DERM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $19.0 million for the third quarter of 2026 Emrosi ® revenues of $9.0 million increased 84% compared to the third quarter of 2025 Company to h

Top Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

DERM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning DERM (Journey Medical Corp). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.

Recent DERM coverage spans earnings, financial news and corporate actions.

What's driving DERM

AlphAI scores every news story that mentions DERM with an AI model for sentiment and relevance, and aggregates insider trades from Journey Medical Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DERM

Score
$DERMMedEarnings

Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate

Journey Medical Corp (DERM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $19.0 million for the third quarter of 2026 Emrosi ® revenues of $9.0 million increased 84% compared to the third quarter of 2025 Company to h

Top Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Journey Medical Corporation Q2 2026 Earnings Call Summary

Journey Medical Corporation reported Q2 2026 positive EBITDA, with total net product revenue up 23% year over year and flat operating expenses. Amrozi revenue was $8.1M, helped by higher prescriptions and ASP gains from more reimbursed channels. Management expects 2026 cash flow positivity, improved formulary coverage, and a July 2026 Urox Cream launch.

$DERMMedAI 8/10

Why is Journey Medical stock rallying today?

Journey Medical Corp (DERM) shares rose 10.9% pre-open after it reported Q2 2026 results. Adjusted EPS was $0.10 vs a $0.02 loss estimate, and revenue was $18.5M vs $18.37M forecast, up 23% YoY. Emrosi sales were $8.1M; GAAP net loss narrowed to about $312k. Company expects positive adjusted EBITDA for 2026.

$DERMMedEarnings

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate

Journey Medical Corp (DERM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi ® revenues were $8.1 million for the s

$DERMLowShareholder vote

Journey Medical Corp (DERM): Submission of Matters to a Vote of Security Holders

Journey Medical Corp (DERM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001867066 0001867066 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor

Journey Medical Corp: Small-Cap Dermatology Stock Walks a Tightrope Between Turnaround Hopes and Volatility Risk

Journey Medical Corp (DERM) is experiencing a period of high volatility, with recent short-term gains but a long-term downward trend. The company's stock performance over the past year shows a significant decline, reflecting skepticism about its growth and financial management despite some analyst "buy" ratings from smaller firms. Investors are advised to be cautious, as the stock sits at an inflection point, requiring clear evidence of sustained revenue growth and operational improvements to justify a higher valuation.

Related tickers